Article
BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $26 Price Target
BTIG analyst Jeet Mukherjee reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Buy and maintains $26 price target.
Comments
- No comments yet. Be the first to comment!